MRK - Merck & Co., Inc.
收市後：
| 前收市價 | 110.93 |
| 開市 | 111.11 |
| 買盤 | 112.55 x 900 |
| 賣出價 | 112.69 x 800 |
| 今日波幅 | 110.72 - 112.73 |
| 52 週波幅 | 83.05 - 119.65 |
| 成交量 | |
| 平均成交量 | 7,549,538 |
| 市值 | 285.513B |
| Beta 值 (5 年，每月) | 0.36 |
| 市盈率 (最近 12 個月) | 21.98 |
| 每股盈利 (最近 12 個月) | 5.12 |
| 業績公佈日 | 2023年8月01日 |
| 遠期股息及收益率 | 2.92 (2.63%) |
| 除息日 | 2023年6月14日 |
| 1 年預測目標價 | 124.21 |
Insider Monkey10 Stocks Jim Cramer Thinks Are Climbing In This Market
In this article, we will be looking at 10 stocks Cramer thinks are climbing in this market. To explore similar stocks, you can take a look at 5 Stocks Jim Cramer Thinks Are Climbing In This Market. “The Winners Make No Sense” On May 9, CNBC’s Mad Money host, Jim Cramer, dived into the current […]
Insider Monkey14 Best Biotech Stocks To Buy According To Hedge Funds
In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […]
Insider Monkey14 Best Healthcare Dividend Stocks to Buy
In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and […]
InvestorPlace7 Stocks That Could Be the Next $2 Trillion-Dollar Companies
As someone who has been writing about stocks professionally for 18 years, I remember when Microsoft (NASDAQ:MSFT), Amazon (NASDAQ:AMZN) and Apple (NASDAQ:AAPL) were the first companies with $1 trillion market capitalizations. There was a great deal of fascination with the milestones at the time. Subsequently, both overcame the $2 trillion mark, and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) has also joined the $1 trillion club. I guess it’s natural that the first companies to cross that huge $1 trilli
InvestorPlace3 Undervalued Pharma Stocks to Buy for High Total Returns
Throughout financial history, equity markets have navigated bull and bear cycles. The same holds true for various sectors. After an extended bull market, there tends to be a price and time correction phase in various sectors. One secret to successful investing is to identify sectors that have been depressed for an extended period. Stocks in this sector tend to be undervalued, and once sentiments reverse, the rally can be massive. My focus in this column is on undervalued pharma stocks to buy. To
Insider Monkey25 Most Prescribed Medication in the World
In this article, we will be taking a look at the 25 most prescribed medication in the world. To skip our detailed analysis, you can go directly to see the 10 most prescribed medication in the world. The advancements that the medical field has accomplished over the past century, and especially in recent decades, has […]
InvestorPlaceShhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs
Everyone seems to be talking about semiconductors, artificial intelligence (AI) and mega-cap tech. However, no one seems to be talking about healthcare stocks to buy. That said, I get it. Semiconductor stocks and AI stocks are the exciting plays in the market, while mega-cap tech is powering the S&P 500 higher. In fact, just a handful of names have driven almost all of the year-to-date gains in the index.InvestorPlace - Stock Market News, Stock Advice & Trading Tips While these stocks are domina
Insider MonkeyBillionaire Ken Fisher’s Top 15 Dividend Stock Picks
In this article, we discuss billionaire Ken Fisher’s top 15 dividend stock picks. You can skip our detailed analysis of Fisher’s hedge fund and his investment philosophy, and go directly to read Billionaire Ken Fisher’s Top 5 Dividend Stock Picks. Ken Fisher’s Fisher Asset Management is one of the most prominent hedge funds in America. […]
Insider Monkey10 “Great” Earnings Reports Jim Cramer is Talking About
In this article, we will take a look at the 10 “great” earnings reports that Jim Cramer is talking about. If you want to explore similar stocks that Jim Cramer likes, you can also take a look at 5 “Great” Earnings Reports Jim Cramer is Talking About. “The Fed is Either Done Tightening, or Almost […]
Insider Monkey15 Biggest Immunotherapy Companies in the World
In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […]
- AASTOCKS
默沙東(MRK.US)估算新冠疫情令本港每年經濟損失約416億港元
美國默沙東藥廠(MRK.US)發佈題為《被忽視的負擔：新冠疫情對各地經濟影響》報告，探討新冠疫情對亞太區五個市場包括澳洲、台灣、南韓、新加坡及香港構成的持續經濟影響。 報告指，假設現時的情況大致維持，估算新冠疫情會為本港帶來每年約416億港元(約53億美元)的經濟損失，相等於年度本地生產總值(GDP)的1.4%。 至於另外四個所調研的市場，新冠疫情帶來的年度經濟損失估計達26億美元至276億美元：新加坡為26億美元(佔GDP的0.6%)、台灣為76億美元(佔GDP的0.9%)、澳洲為170億美元(佔GDP的1%)、南韓為275億美元(佔GDP的1.6%)。 展望未來，估計新冠疫情可為本港造成每年約40億港元至1,087億港元的潛在經濟損失，相等於GDP的0.1%至3.8%，視乎疫情發展及實際情況。 報告發現，間接成本是新冠疫情目前經濟負擔及未來經濟預測的主要因素，而感染率和疾病嚴重程度在未來的變化將明顯影響經濟成本。即使新冠疫情由「全球大流行」階段逐漸轉變為「風土病」，報告預測的其構成的間接成本很可能會維持高企。間接成本主要成因包括生產力流失(如受感染後不能工作)，以及照顧兒童和長者等
- infocast
默沙東估算新冠疫情會為香港帶來每年約416億港元經濟損失
美國默沙東藥廠(MSD)發佈題為《被忽視的負擔:新冠疫情對各地經濟影響》報告,探討新冠疫情對亞太區5個市場包括澳洲、台灣、南韓、新加坡及香港構成的持續經濟影響。報告指,假設現時的情況大致維持,估算新冠疫情會為香港帶來每年約416億港元(約53億美元)的經濟損失,相等於年度本地生產總值(GDP)的1.4%。至於另外4個所調研的市場,新冠疫情帶來的年度經濟損失估計達26-276億美元;新加坡為26億美元(佔GDP 的0.6%）、台灣為76億美元(佔 GDP 的0.9%)、澳洲為170億美元(佔 GDP 的1%）、南韓為275億美元(佔 GDP 的1.6%)。報告發現,間接成本是新冠疫情目前經濟負擔及未來經濟預測的主要因素,而感染率和疾病嚴重程度在未來的變化將明顯影響經濟成本。即使新冠疫情由「全球大流行」階段逐漸轉變為「風土病」,報告預測的其構成的間接成本很可能會維持高企。間接成本主要成因包括生產力流失(如受感染後不能工作),以及照顧兒童和長者等所衍生的連鎖影響。本港人口中有三個群組特別於疫情期間帶來最重比率的間接經濟損失,分別為易受感染人士、在職人士及醫護人員。易受感染人士(指60歲以上長
BenzingaInsurers Can't Use War Argument: Court Rules in Favor of Merck in $1.4 Billion Cyberattack Coverage Case
A New Jersey appellate court ruled that a group of insurers can’t use war as an argument to deny Merck & Co Inc (NYSE: MRK) coverage from the $1.4 billion cyberattack that happened in 2017. The court said the insurers must help the pharma giant cover losses from the cyber attack that the U.S. blamed on Russia. New Jersey appellate division judges said that the NotPetya cyberattack didn’t involve military action and can’t be excluded from coverage under a warlike-act exclusion. “The exclusion of
Insider Monkey10 Best May Dividend Stocks To Buy
In this article, we discuss 10 best May dividend stocks to buy. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Best May Dividend Stocks To Buy. Dividend stocks have been a popular investment option for decades, providing investors with a steady stream […]
BenzingaFDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting
The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for metastatic castration-resistant prostate cancer (mCRPC). In 2017, AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) collaborated to co-develop and co-commercialise Lynparza and Koselugo (selumetinib) for multiple cancer types. Ahead of the meeting, the
BenzingaWhy Merck Stock Is Trading Higher Today
Merck & Co Inc's (NYSE: MRK) Q1 sales reached $14.49 billion, down 9% Y/Y, beating the consensus of $13.79 billion. Excluding Lagevrio (COVID-19 treatment), sales growth was 11%; excluding Lagevrio and the impact of foreign exchange, growth was 15%. Pharmaceutical sales decreased by 10% to $12.72 billion, primarily due to lower sales in virology, mainly attributable to Lagevrio, and diabetes, partially offset by growth in oncology, vaccines, and hospital acute care. Lagevrio Q1 sales declined 88
- AASTOCKS
《美股業績》默沙東(MRK.US)首季業績勝預期 上調全年盈利指引
默沙東(MRK.US)公布，今年首季銷售額為144.87億美元(下同)，按年下跌9%，但高於市場預期的137.8億元；盈利為28.2億元，按年減少35%；經調整每股盈利為1.4元，同樣高於市場預期的1.32元。 公司稍為提高今年全年每股盈利預測，最新料介乎6.88元至7元。 業績公布後默沙東周四(27日)美股開市初段靠穩，升0.7%，報114.18元。(ek/m)~ 阿思達克財經新聞 網址: www.aastocks.com
Insider Monkey11 Best Mid-Cap Healthcare Stocks To Buy Now
In this article, we discuss 11 best mid-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Mid-Cap Healthcare Stocks To Buy Now. The healthcare industry outlook is currently uncertain due to a combination of factors such as economic troubles, a shortage of healthcare workers, […]
InvestorPlace3 Pharma Stocks That Could See a Surge in Demand in 2023
As 2023 unfolds, the pharmaceutical space is blossoming with new opportunities, sparking curiosity for those looking to buy some pharma stocks. With the iShares Biotechnology ETF (NASDAQ:IBB) ticking upward, for the most part, this year, investors who dive into pharma stocks need to capitalize on the sector’s positive momentum. Many experts suggest that we are in the golden age of biotechnology, with scientific breakthroughs transforming how we treat and prevent diseases. Hence, pharma stocks to
Insider Monkey12 Best Pharma Dividend Stocks To Buy in 2023
In this article, we discuss 12 best pharma dividend stocks to buy in 2023. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2023. The pharmaceutical industry in the US is one of the largest in […]
- AASTOCKS
《大行報告》花旗升默沙東(MRK.US)評級至「買入」 目標價上調至130美元
花旗發表研究報告，將默沙東(MRK.US)的投資評級從「中性」上調至「買入」，並基於估值預測將目標價從105美元上調至130美元，看好公司旗下的ADC藥物MK-2870及SKB-264(TROP2)，以及用於治療肺動脈高壓的藥物Sotatercept及新型降膽固醇藥物MK-0616的表現。 該行又指，投資者較少關注默沙東MRK通過與科倫博泰生物醫藥達成的ADC許可協議，預測公司2033年風險調整後銷售額將達到約60億美元。(gc/a)~ 阿思達克財經新聞 網址: www.aastocks.com
Yahoo FinanceModerna stock plunges following mixed analyst reviews of cancer vaccine data
Moderna stock plunges following mixed analyst reviews of cancer vaccine data
BenzingaModerna, Merck's Cancer Vaccines Exhibit Positive Outcomes Under Midstage Trial
Moderna, Inc (NASDAQ: MRNA) and Merck & Company, Inc's (NYSE: MRK) cancer vaccine exhibited positive results against relapse for melanoma patients, results from a midstage trial showed. About 79% of high-risk melanoma patients who got the personalized vaccine and Merck's immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone, the Wall Street reports citing researchers. Some 157 patients with stage three or four melanom
BenzingaRussia Warns As Finland Joins NATO, Spotify Highlights Struggle With Live Audio, Anticompetitive Charges Against Activision Blizzard: Today's Top Stories
Benzinga Finland Joins NATO Doubling Border Length, Russia Issues Warning The Finland foreign minister signed the accession document, and Finland has become the 31st member of the North Atlantic Treaty Organization (NATO) security alliance. The move is a strategic and political blow to Russia's Vladimir Putin, who has repeatedly complained about NATO's expansion toward Russia and partly used that as a justification for invading Ukraine. Dogecoin Fans Ask Elon Musk To Take It To The Moon As Offic
BenzingaFDA Approves Merck's Keytruda Combined With Seagen/Astellas's Padcev For Advanced Urothelial Cancer
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in combination with Astellas Pharma Inc (OTC: ALMPF) & Seagen Inc's (NASDAQ: SGEN) Padcev (enfortumab vedotin-ejfv) locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Related: US Senators Warren, Sanders Urge 'Close Scrutiny' On Merck's Keytruda-R